Core Viewpoint - Jiuan Medical reported a significant decline in revenue and net profit for the third quarter of 2025, indicating potential challenges in its business operations [2] Financial Performance - The company achieved a revenue of 304 million yuan for the third quarter of 2025, representing a year-on-year decrease of 58.98% [2] - The net profit attributable to shareholders was 669 million yuan, down 12.78% compared to the previous year [2] - Basic earnings per share stood at 1.5574 yuan [2]

Core Viewpoint - Jiuan Medical reported a significant decline in revenue for the first three quarters of 2025, while net profit showed a year-on-year increase, indicating a mixed financial performance [1] Financial Performance Summary - The company's revenue for the first three quarters reached 1.069 billion yuan, a year-on-year decrease of 48.89% [1] - The net profit attributable to shareholders for the same period was 1.589 billion yuan, reflecting a year-on-year growth of 16.11% [1] - In the third quarter, the company achieved a revenue of 304 million yuan, which represents a year-on-year decline of 58.98% [1] - The net profit for the third quarter was 669 million yuan, showing a year-on-year decrease of 12.78% [1]

Core Viewpoint - Jiuan Medical (002432.SZ) reported a significant decline in revenue for the first three quarters, while net profit showed growth, indicating a mixed financial performance [1] Financial Performance - The company's operating revenue for the first three quarters was 1.069 billion yuan, a year-on-year decrease of 48.89% [1] - The net profit attributable to shareholders of the listed company reached 1.589 billion yuan, reflecting a year-on-year increase of 16.11% [1] - The net profit attributable to shareholders after deducting non-recurring gains and losses was 1.578 billion yuan, which is a year-on-year growth of 14.60% [1]

天津九安医疗电子股份有限公司 关于与专业投资机构共同投资的公告 证券代码：002432 证券简称：九安医疗 公告编号：2025-085 本公司及董事会全体成员保证信息披露的内容真实、准确和 完整，没有虚假记载、误导性陈述或重大遗漏。 一、对外投资概述 为发挥创业投资支持科技创新的重要作用，培育壮大战略性新兴产业和未来 产业，推动重大科技成果向现实生产力转化，加快实现高水平科技自立自强，培 育发展新质生产力，天津市拟设立天津市海河创业投资基金合伙企业（有限合伙） （暂定名，最终以实际注册名称为准，以下简称"海河创投基金"）。 （1）营业执照：91120118MA05P8JHX8 （2）成立时间：2017年3月28日 （3）注册资本：20,000.00万元人民币 （4）注册地址：天津自贸试验区（中心商务区）响螺湾旷世国际大厦1栋 1509-06 （5）经营范围：受托管理股权投资企业，从事投资管理及相关咨询服务。 （依法须经批准的项目，经相关部门批准后方可开展经营活动） 天津九安医疗电子股份有限公司（以下简称"公司"）于 2025 年 10 月 24 日， 召开第六届董事会第二十八次会议，审议通过了《关于与专业投资 ...

Group 1 - The core point of the article is that Jiuan Medical (SZ 002432) held its 28th meeting of the sixth board of directors on October 24, 2025, to discuss investment proposals with professional investment institutions [1] - For the first half of 2025, Jiuan Medical's revenue composition was as follows: medical devices accounted for 87.74%, internet medical products and services accounted for 6.57%, retail business accounted for 5.03%, and other industries accounted for 0.66% [1] - As of the time of reporting, Jiuan Medical's market capitalization was 18.7 billion yuan [1] Group 2 - The article mentions that the Chinese innovative drug sector has sold overseas licenses worth 80 billion USD this year, highlighting the hot secondary market in biomedicine [1] - A dialogue with Lu Gang, a partner at Chuangdong Investment, indicates that while the secondary market is thriving, the primary market is facing challenges in fundraising [1]

Group 1 - The core point of the article is that Jiuan Medical reported a significant decline in revenue for the first three quarters of 2025, while net profit increased, indicating a mixed performance [1] Group 2 - Jiuan Medical's revenue for the first three quarters of 2025 was approximately 1.069 billion yuan, a year-on-year decrease of 48.89% [1] - The net profit attributable to shareholders of the listed company was approximately 1.589 billion yuan, a year-on-year increase of 16.11% [1] - Basic earnings per share were approximately 3.66 yuan, reflecting a year-on-year increase of 14.74% [1] - As of the report, Jiuan Medical's market capitalization was 18.7 billion yuan [2]

Core Viewpoint - Jiuan Medical (002432) reported a significant decline in revenue for Q3 2025, indicating potential challenges in the company's operational performance [1] Financial Performance - In Q3 2025, the company achieved a revenue of 304 million yuan, representing a year-on-year decrease of 58.98% [1] - The net profit attributable to shareholders for Q3 2025 was 669 million yuan, down 12.78% year-on-year [1] - For the first three quarters of 2025, the total revenue was 1.069 billion yuan, reflecting a year-on-year decline of 48.89% [1] - The net profit attributable to shareholders for the first three quarters was 1.589 billion yuan, which is an increase of 16.11% compared to the same period last year [1]

关于与专业投资机构共同投资的进展公告 本公司及董事会全体成员保证信息披露的内容真实、准确和完整， 没有虚假记载、误导性陈述或重大遗漏。 一、投资的基本情况 天津九安医疗电子股份有限公司（以下简称"公司"）全资子公司 Andon Ho ng Kong Co., Limited（以下简称"九安香港"）以有限合伙人身份使用自有资金 人民币 31,298.85 万元人民币或等值美元，与北京尚势投资管理有限公司（以下 简称"尚势投资"）共同设立天津市九尚创业投资合伙企业（有限合伙）（以下简 称"九尚创投"）。九尚创投及尚势投资共同设立天津九尚一号管理咨询合伙企业 （有限合伙）（以下简称"九尚一号"）。本次投资的目的是以九尚一号为主体向 境内创业投资型基金、初创企业等进行投资。具体内容详见公司于 2023 年 12 月 29 日披露的《关于与专业投资机构共同投资的公告》（公告编号：2023-077）。 二、投资的进展情况 证券代码：002432 证券简称：九安医疗 公告编号：2025-086 天津九安医疗电子股份有限公司 九安香港于近日收到管理人（暨普通合伙人）尚势投资的通知，九尚创投已 募集完成，截至目前已收到全体合伙 ...

证券代码：002432 证券简称：九安医疗 公告编号：2025-083 天津九安医疗电子股份有限公司(以下简称"公司"或"本公司")于2025年10月 22日以通讯方式发出召开第六届董事会第二十八次会议的通知，会议于2025年10 月24日在公司会议室以现场和通讯表决相结合方式召开。本次会议由公司董事长 刘毅先生主持，会议应参加的董事6名，实际参加的董事6名，全体监事、公司高 级管理人员列席了会议，符合《公司法》及《公司章程》的规定。根据《公司章 程》规定，与会董事就会议议案进行了审议、表决并通过了如下议案： 天津九安医疗电子股份有限公司 第六届董事会第二十八次会议决议公告 本公司及董事会全体成员保证信息披露的内容真实、准确和完整， 没有虚假记载、误导性陈述或重大遗漏。 具 体 内 容 详 见 公 司 同 日 刊 登 于 《 证 券 时 报 》 及 巨 潮 资 讯 网 （http://www.cninfo.com.cn）的《关于与专业投资机构共同投资的公告》（公告 编号：2025-085）。 特此公告。 天津九安医疗电子股份有限公司董事会 2025 年 10 月 25 日 一、以6票同意、0票反对、0票弃权的 ...

Core Viewpoint - Ji'an Medical reported a significant decline in revenue and net profit for the third quarter, indicating potential challenges in the company's financial performance [1] Financial Performance - The company's revenue for the third quarter was 304 million yuan, a year-on-year decrease of 58.98% [1] - Net profit for the third quarter was 669 million yuan, down 12.78% year-on-year [1] - For the first three quarters, total revenue was 1.069 billion yuan, reflecting a year-on-year decline of 48.89% [1] - Net profit for the first three quarters was 1.589 billion yuan, which represents a year-on-year increase of 16.11% [1]